TimothyRWassenaarMD

Oncology • Waukesha, WI

Hematology at ProHealth Care/Regional Cancer Center

Join to view full profile

Dr. Wassenaar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wassenaar's full profile

Already have an account?

Office
N16W24131 Riverwood Dr
Waukesha, WI 53188
Phone+1 262-969-5690

Fax+1 262-696-0769
Is this information wrong?

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2002 - 2005
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2002

Certifications & Licensure

WI State Medical License 2003 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Start of enrollment: 2009 Sep 01
Recruiting
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer Start of enrollment: 2013 Dec 01
Completed
Not Applicable
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2018 Oct 26
Active, not recruiting
Phase 3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma Start of enrollment: 2023 Dec 13
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, William J Edenfield, Elizabeth Claire Dees, ...> ;Cancer Research Communications. 2023 Jul 1
6 citations
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Tomlins, S., Khazanov, N., Bulen, B., Hovelson, D., Shreve, M., Lamb, L., Matrana, M., Burkard, M., Yang, E., Edenfield, W., Dees, E., Onitilo, A., Thompson, M., Buchs...> ;Communications Medicine. 2023 Feb 7
1 citations
Barriers and facilitators to the use of survivorship care plans by hematopoietic stem cell transplant survivors and clinicians.
Colleen M. Morken, Amye J. Tevaarwerk, Mark B. Juckett, Amanda K. Swiecichowski, James E. Haine, Xiao Zhang, Zachary T. Williams, Kirsten Norslien, Bethaney Campbell, ...> ;Supportive Care in Cancer. 2021 Sep 5
13 citations
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Scott A. Tomlins, Daniel H. Hovelson, Jennifer Marie Suga, Daniel M. Anderson, Han A. Koh, Elizabeth Claire Dees, Brendan McNulty, Mark E. Burkard, Michael Guarino, Ja...> ;JCO Precision Oncology. 2021 Aug 19
17 citations
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Rami S. Komrokji, Kathy L. McGraw, Jaroslaw P. Maciejewski, Jessica K. Altman, Puneet S. Cheema, David F. Claxt...> ;Journal of Clinical Oncology. 2021 Jan 13
12 citations
Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice.
Alexandra Hua, Mary E. Sesto, Xiao Zhang, Timothy R Wassenaar, Amye J. Tevaarwerk> ;Journal of Cancer Education. 2020 Apr 1
102 citations
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Ne...
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, P. J. Stella, Brian L. Burnette, Melinda L. Telli, Della F. Makower, Pun...> ;Journal of Clinical Oncology. 2018 Apr 17
Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients.
Wassenaar, T.,Black, J.,Kahl, B.,Schwartz, B.,Longo, W.,Mosher, D.,Williams, E.> ;Hematol Oncol. 2008 Jul 10
55 citations
Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer.
Timothy R. Wassenaar, Jens C. Eickhoff, Daniel R. Jarzemsky, Stevens S. Smith, Marilyn L. Larson, Joan H. Schiller> ;Journal of Thoracic Oncology. 2007 Aug 1
Join now to see all

Abstracts/Posters

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Timothy R. Wassenaar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019